Skip to main content
SpringerLink
Log in

One-Stage Factor VIII Assays

  • Protocol
  • First Online:
Hemostasis and Thrombosis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1646))

Abstract

Coagulation factor assays using one-stage methodology are widely used to measure factor levels for the purpose of detecting a deficiency, or to monitor replacement therapy. In this chapter, we focus on a method to measure Factor VIII coagulant activity (FVIII:C) by the one-stage assay (FVIII:C-1), with extra information provided to also allow this method to apply to Factor IX (FIX), Factor XI (FXI), and Factor XII (FXII). From the perspective of laboratory testing, these factors are components of the “intrinsic” coagulation pathway and are all measured in test systems based on the correction of the Activated Partial Thromboplastin Time (APTT). Factor activity is assessed by measuring the ability of an unknown sample to correct the prolonged APTT of factor-deficient plasma (deficient in the factor of interest), relative to the effect of a known calibrator. These assays are used for the diagnosis of the many causes of reduced factor levels, including those causing a prolonged APTT. It is important for laboratory staff to understand the impact of method variations, limitations, and result interpretation and these aspects are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the Factor VIII and Factor IX Subcommittee (2001) Definitions in haemophilia. Thromb Haemost 85:560

    CAS  PubMed  Google Scholar 

  2. Preston FE, Kitchen S, Jennings I, Woods TAL, Makris M (2004) SSC/ISTH classification of haemophilia A: can haemophilia center laboratories achieve the new criteria? J Thromb Haemost 2:271–274

    Article  CAS  PubMed  Google Scholar 

  3. Peyvandi F, Oldenburg J, Friedman KD (2015) A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 14:248–261

    Article  Google Scholar 

  4. Barrowcliffe TW, Raut S, Sands D, Hubbard AR (2001) Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 28:247–256

    Article  Google Scholar 

  5. Duncan E, Collecutt M, Street A (2013) Nijmegen-Bethesda assay to measure factor VIII inhibitors. In: Monagle P (ed) Haemostasis: methods and protocols, methods in molecular biology, vol 992. Springer, London, UK, pp 321–333

    Chapter  Google Scholar 

  6. Kitchen S, Hayward C, Negrier C, Dargaud Y (2010) New developments in laboratory diagnosis and monitoring. Haemophilia 16(Suppl. 5):61–66

    Article  PubMed  Google Scholar 

  7. Duncan EM, Rodgers SE, McRae SJ (2013) Diagnostic testing for mild Haemophilia a in patients with discrepant one-stage, two-stage and chromogenic FVIII:C assays. Semin Thromb Hemost 39:272–282

    Article  CAS  PubMed  Google Scholar 

  8. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M, on behalf of the British Committee for Standards in Haematology (2013) Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 35:1–13

    Article  CAS  PubMed  Google Scholar 

  9. Kitchen S, Signer-Romero K, Key NS (2015) Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia 21:550–557

    Article  CAS  PubMed  Google Scholar 

  10. Favaloro EJ, Meijer P, Jennings I, Soufi J, Bonar RA, Kitchen DP et al (2013) Problems and solutions in laboratory testing for haemophilia. Semin Thromb Hemost 39:816–833

    Article  PubMed  Google Scholar 

  11. Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB, on behalf of the SSC Sub-committees on Factor VIII/Factor IX and von Willebrand factor of ISTH (2011) Value assignment of the WHO 6th international standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). J Thromb Haemost 9:2100–2102

    Article  CAS  PubMed  Google Scholar 

  12. Favaloro EJ, Soltani S, McDonald J (2004) Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. Am J Clin Pathol 122:686–692

    Article  CAS  PubMed  Google Scholar 

  13. Rodgers SE, Wong A, Gopal RD, Dale BJ, Duncan EM, McRae SJ (2014) Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thromb Res 134:160–164

    Article  CAS  PubMed  Google Scholar 

  14. Westgard JO (2010) QC–the calculations. In: Basic QC practices, 3rd edn. Westgard QC, Inc., Madison, WI, pp 177–193. Chapter 13

    Google Scholar 

  15. Westgard JO (2003) Method validation: reference interval transference. In: Basic method validation, 2nd edn. Westgard QC, Inc., Madison, WI, pp 164–171. Chapter 15

    Google Scholar 

  16. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L (2005) Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 16:597–605

    Article  CAS  PubMed  Google Scholar 

  17. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ (2000) Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 108:259–264

    Article  CAS  PubMed  Google Scholar 

  18. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P (1987) Development of the human coagulation system in the full-term infant. Blood 70:165–172

    CAS  PubMed  Google Scholar 

  19. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A et al (2006) Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372

    CAS  PubMed  Google Scholar 

  20. Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R et al (2015) Inhibitor development and mortality in non-severe haemophilia A. J Thromb Haemost 13:1217–1225

    Article  CAS  PubMed  Google Scholar 

  21. Ay C, Thom K, Abu-Hamdeh F, Horvath B, Quehenberger P, Male C et al (2010) Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. Haemophilia 16:111–117

    Article  CAS  PubMed  Google Scholar 

  22. Lyall H, Hill M, Westby J, Grimley C, Dolan G (2008) Tyr346-Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A? Haemophilia 14:78–80

    CAS  PubMed  Google Scholar 

  23. Verbruggen B, Meijer P, Novakova I, Van Heerde W (2008) Diagnosis of factor VIII deficiency. Haemophilia 14(Suppl 3):76–82

    Article  CAS  PubMed  Google Scholar 

  24. Mikaelsson M, Oswaldsson U, Sandberg H (1998) Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 4:646–650

    Article  CAS  PubMed  Google Scholar 

  25. Manco-Johnson MJ, Nuss R, Jacobson LJ (2000) Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 136:74–79

    Article  CAS  PubMed  Google Scholar 

  26. Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K (2016) The effect of direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 48:60–71

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, SA Pathology, Frome Rd, Adelaide, SA, 5000, Australia

    Elizabeth Duncan & Susan Rodgers

Authors
  1. Elizabeth Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Rodgers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Duncan .

Editor information

Editors and Affiliations

  1. Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia

    Emmanuel J. Favaloro

  2. Section of Clinical Biochemistry, University of Verona, Verona, Italy

    Giuseppe Lippi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Duncan, E., Rodgers, S. (2017). One-Stage Factor VIII Assays. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7196-1_20

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7194-7

  • Online ISBN: 978-1-4939-7196-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation